AlzeCure Pharma AB (publ) (STO:ALZCUR)

AlzeCure Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	11.64	11.88	11.47	10.6	10.17	11.27
Research & Development	51.42	37.49	24.8	27.71	46.18	66.72
Other Operating Expenses	-3.47	-1.4	-0.28	0.04	0.22	0.16
Operating Expenses	59.59	47.97	35.99	38.34	56.57	78.14
Operating Income	-59.59	-47.97	-35.99	-38.34	-56.57	-78.14
Interest Expense	-0.26	-0.27	-0.35	-0.01	-0	-0
Interest & Investment Income	0.51	0.49	0.93	1.1	0.21	0.15
Currency Exchange Gain (Loss)	0.11	0.08	0.03	0.08	0.13	0.22
Pretax Income	-59.23	-47.67	-35.38	-37.17	-56.24	-77.78
Income Tax Expense	-0.01	-0.02	-0.03	-	-	-
Net Income	-59.22	-47.65	-35.35	-37.17	-56.24	-77.78
Net Income to Common	-59.22	-47.65	-35.35	-37.17	-56.24	-77.78
Shares Outstanding (Basic)	107	100	77	62	48	38
Shares Outstanding (Diluted)	107	100	77	62	48	38
Shares Change (YoY)	28.01%	30.26%	24.26%	30.17%	26.30%	-
EPS (Basic)	-0.55	-0.47	-0.46	-0.60	-1.18	-2.06
EPS (Diluted)	-0.55	-0.47	-0.46	-0.60	-1.18	-2.06
Free Cash Flow	-41.26	-34.59	-34.35	3.06	-99.91	-70.69
Free Cash Flow Per Share	-0.39	-0.34	-0.45	0.05	-2.10	-1.87
EBITDA	-58.36	-46.7	-35	-37.87	-56	-77.57
D&A For EBITDA	1.24	1.27	1	0.48	0.57	0.58
EBIT	-59.59	-47.97	-35.99	-38.34	-56.57	-78.14

Source: S&P Global Market Intelligence. Standard template. Financial Sources.